Situation Report: Mpox in Children
Share this article
Renaming to Mpox
NETEC is in the process of updating its web pages with the term “mpox” to reduce stigma and other issues associated with prior terminology. This change is aligned with the World Health Organization decision.
Mpox Outbreak Extends to Pediatric Population
CDC Guidance for Pediatrics
See the CDC’s “Clinical Considerations for Monkeypox in Children and Adolescents” (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/pediatric.html, Accessed 8/23/2022) guidance for the latest information on the 2022 monkeypox outbreak.
Cases of Mpox in Children
To date, dozens of mpox cases have been reported in children globally, including a number of cases in the United States (CDC, https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html, Accessed 8/23/2022). Currently, the risk of mpox to children and adolescents remains low.
However mpox is spread through prolonged, physical contact and therefore household transmission is possible. Individuals should avoid direct skin-to-skin contact with someone suspected or confirmed of having mpox and avoid contact with clothing, bedding, or towels they may have used. See CDC guidance for cleaning and disinfecting shared spaces to reduce the risk of transmission (CDC, https://www.cdc.gov/poxvirus/monkeypox/specific-settings/home-disinfection.html, Accessed 8/23/2022).
Identifying Risks and Symptoms of Mpox in Children
Mpox rash can appear similar to other common childhood rashes. Pediatricians should consider mpox if a patient presents with a rash and generalized symptoms (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/clinical-recognition.html, 8/23/2022) and gather a thorough clinical history to identify any possible epidemiological risk factors.
While most cases in this outbreak have not led to severe disease, factors that increase this risk include immunocompromising conditions and a history of eczema or another skin condition. The risk for severe disease increases for children under 8 years of age. Learn more about the factors for high risk of severe disease from mpox (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html, Accessed 8/23/2022).
Vaccines and Treatments for Kids
Two vaccines are available for children with a confirmed or suspected high-risk exposure. Learn more about the vaccines (CDC, https://www.cdc.gov/poxvirus/monkeypox/considerations-for-monkeypox-vaccination.html, Accessed 8/23/2022).
- JYNNEOS has received FDA Emergency Use Authorization for use in children and adolescents under 18 years of age.
- ACAM2000 is available under expanded access for an investigational new drug but is not recommended for children under 12 months old, those with specific underlying conditions, or children in contact with immunocompromised individuals.
The first-line treatment for mpox, tecovirimat, is available via expanded access for an investigational new drug for use in children and adolescents. There is limited data on the use of these vaccines and treatments in children, and providers should discuss the risks and benefits with patients and caregivers. See the CDC’s guidance for using tecoviramat (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html, Accessed 8/23/2022).
Mpox and Pediatrics: What Clinicians Need to Know
As the 2022 global mpox outbreak continues to spread in the U.S. and abroad, pediatricians should consider how mpox may affect their patients.
